RNA m6A methylation regulators in ovarian cancer

被引：38

作者：

Guo, Jialu ^{[1
,2
]}

Zheng, Jianfeng ^{[2
,3
]}

Zhang, Huizhi ^{[1
]}

Tong, Jinyi ^{[1
,2
]}

机构：

[1] Zhejiang Chinese Med Univ, Dept Sch Clin Med 4, Hangzhou 310053, Zhejiang, Peoples R China

[2] Hangzhou Matern & Child Hlth Care Hosp, Hangzhou Womens Hosp, Dept Obstet & Gynecol, Hangzhou 310008, Zhejiang, Peoples R China

[3] Nanjing Med Univ, Affiliated Hangzhou Hosp, Dept Obstet & Gynecol, Hangzhou 310008, Zhejiang, Peoples R China

来源：

CANCER CELL INTERNATIONAL | 2021年 / 21卷 / 01期

关键词：

Ovarian cancer; Biomarker; N6-methyladenosine; Regulators; PROMOTES CELL-PROLIFERATION; TUMOR 1-ASSOCIATING PROTEIN; SERUM RESPONSE FACTOR; STEM-LIKE CELLS; GENE-EXPRESSION; NUCLEAR-RNA; IMP3; EXPRESSION; ANTICANCER ACTIVITY; THERAPEUTIC TARGET; BINDING-PROTEIN;

D O I：

10.1186/s12935-021-02318-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

N6-methyladenosine (m6A) is the most abundant RNA modification of mammalian mRNAs and plays a vital role in many diseases, especially tumours. In recent years, m6A has become the topic of intense discussion in epigenetics. M6A modification is dynamically regulated by methyltransferases, demethylases and RNA-binding proteins. Ovarian cancer (OC) is a common but highly fatal malignancy in female. Increasing evidence shows that changes in m6A levels and the dysregulation of m6A regulators are associated with the occurrence, development or prognosis of OC. In this review, the latest studies on m6A and its regulators in OC have been summarized, and we focus on the key role of m6A modification in the development and progression of OC. Additionally, we also discuss the potential use of m6A modification and its regulators in the diagnosis and treatment of OC.

引用

页数：13

共 167 条

[1] m6A: Signaling for mRNA splicing [J].

Adhikari, Samir ;

Xiao, Wen ;

Zhao, Yong-Liang ;

Yang, Yun-Gui .

RNA BIOLOGY, 2016, 13 (09) :756-759

[2] HNRNPA2B1 Is a Mediator of m6A-Dependent Nuclear RNA Processing Events [J].

Alarcon, Claudio R. ;

Goodarzi, Hani ;

Lee, Hyeseung ;

Liu, Xuhang ;

Tavazoie, Saeed ;

Tavazoie, Sohail F. .

CELL, 2015, 162 (06) :1299-1308

[3] N6-methyladenosine marks primary microRNAs for processing [J].

Alarcon, Claudio R. ;

Lee, Hyeseung ;

Goodarzi, Hani ;

Halberg, Nils ;

Tavazoie, Sohail F. .

NATURE, 2015, 519 (7544) :482-+

[4] AXL-Driven EMT State as a Targetable Conduit in Cancer [J].

Antony, Jane ;

Huang, Ruby Yun-Ju .

CANCER RESEARCH, 2017, 77 (14) :3725-3732

[5]

Ariyaratana Suzie, 2007, Expert Reviews in Molecular Medicine, V9, DOI 10.1017/S1462399407000336

[6] WTAP is a novel oncogenic protein in acute myeloid leukemia [J].

Bansal, H. ;

Yihua, Q. ;

Iyer, S. P. ;

Ganapathy, S. ;

Proia, D. ;

Penalva, L. O. ;

Uren, P. J. ;

Suresh, U. ;

Carew, J. S. ;

Karnad, A. B. ;

Weitman, S. ;

Tomlinson, G. E. ;

Rao, M. K. ;

Kornblau, S. M. ;

Bansal, S. .

LEUKEMIA, 2014, 28 (05) :1171-1174

[7] Role of RNA modifications in cancer [J].

Barbieri, Isaia ;

Kouzarides, Tony .

NATURE REVIEWS CANCER, 2020, 20 (06) :303-322

[8] Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? [J].

Bell, Jessica L. ;

Waechter, Kristin ;

Muehleck, Britta ;

Pazaitis, Nikolaos ;

Koehn, Marcel ;

Lederer, Marcell ;

Huettelmaier, Stefan .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2013, 70 (15) :2657-2675

[9] Is There a Role for Ovarian Cancer Screening in High-Risk Women? [J].

Berchuck, Andrew ;

Havrilesky, Laura J. ;

Kauff, Noah D. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) :1384-+

[10] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

← 1 2 3 4 5 6 7 8 9 10 →